Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology <l ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi has entered into an agreement to acquire Blueprint Medicines Corp., a U.S.-based biopharma company specializing in ...